Author Details

Czartoryska-Arłukowicz, Bogumiła

  • Vol 7, Supp. C (2011) - CASE REPORT
    Molekularnie ukierunkowana terapia pacjentki z jasnokomórkowym rakiem nerki
    Abstract  PDF (Polish)
  • Vol 7, No 4 (2011) - REVIEW ARTICLES
    The therapy interfering EGFR activation in breast cancer patients
    Abstract  PDF (Polish)
  • Vol 7, Supp. A (2011) - CASE REPORT
    Chora z rozsianym rakiem piersi z nadekspresją HER2 leczona lapatynibem z kapecytabiną po progresji w trakcie leczenia trastuzumabem
    Details  PDF (Polish)
  • Vol 7, Supp. D (2011) - CASE REPORT
    Lapatynib z kapecytabiną w leczeniu chorej na raka piersi z przerzutami do ośrodkowego układu nerwowego
    Details
  • Vol 7, Supp. C (2011) - CASE REPORT
    Leki molekularnie ukierunkowane w terapii raka jasnokomórkowego
    Abstract  PDF (Polish)
  • Vol 9, No 3 (2013) - REVIEW ARTICLES
    Significance of cooperation between pathomorphologist and oncologist in the treatment of gastrointestinal stromal tumors (GIST)
    Abstract  PDF (Polish)
  • Vol 10, No 6 (2014) - CASE REPORTS
    Durable response to fulvestrant therapy in a hormone receptor-positive metastatic breast cancer patient with massive metastatic disease
    Abstract  PDF (Polish)
  • Vol 12, No 1 (2016) - REVIEW ARTICLES
    The role of anthracyclines and dose dense therapy in an adjuvant setting, in HER2-positive early breast cancer, in clinical practice
    Abstract  PDF  HTML
  • Vol 11, Supp. G (2015) - CASE REPORT
    Durable disease stabilization associated with octreotide LAR treatment in a patient with metastatic carcinoid of the small intestine
    Abstract  PDF (Polish)
  • Ahead of print - ORIGINAL ARTICLES
    Systemic treatment of patients with advanced pancreatic cancer — is there still a place for gemcitabine in the first-line setting? Experience of Polish oncology centers
    Abstract  PDF
  • Ahead of print - ORIGINAL ARTICLES
    Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index as clinical predictive and prognostic markers in patients with advanced pancreatic cancer receiving gemcitabine monotherapy
    Abstract  PDF

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl